6vlx | pdb_00006vlx

Crystal structure of FabI from Alistipes finegoldii

spinqualitylabelsall models 6vlx, resolution 1.72Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 6vlx is a 2 chain structure with sequence from Alistipes finegoldii. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 1.72Å Ligands: GOL Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Function A0A174E195_9BACT Publication Abstract from PubMed Enoyl-acyl carrier protein reductase (FabI) catalyzes a rate-controlling step in bacterial fatty-acid synthesis and is a target for antibacterial drug development. A phylogenetic analysis shows that FabIs fall into four divergent clades. Members of clades 1-3 have been structurally and biochemically characterized, but the fourth clade found in members of phylum Bacteroidetes is uncharacterized. Here, we identified the unique structure and conformational changes that distinguish clade 4 FabIs. Alistipes finegoldii is a prototypical Bacteroidetes inhabitant of the gut microbiome. We found that A. finegoldii FabI (AfFabI) displays cooperative kinetics and uses NADH as a cofactor, and its crystal structure at 1.72 A resolution showed that it adopts a Rossmann fold as do other characterized FabIs. It also disclosed a C-terminal extension that forms a helix-helix interaction that links the protomers as a unique feature of AfFabI. An AfFabI*NADH crystal structure at 1.86 A resolution revealed that this feature undergoes a large conformational change to participate in covering the NADH-binding pocket and establishing the water channels that connect the active site to the central water well. Progressive deletion of these interactions led to catalytically compromised proteins that fail to bind NADH. This unique conformational change imparted a distinct shape to the AfFabI active site that renders it refractory to a FabI drug that targets clade 1 and 3 pathogens. We conclude that the clade 4 FabI, found in the Bacteroidetes inhabitants of the gut, have several structural features and conformational transitions that distinguish them from other bacterial FabIs. The genome of a Bacteroidetes inhabitant of the human gut encodes a structurally distinct enoyl-acyl carrier protein reductase (FabI).,Radka CD, Frank MW, Yao J, Seetharaman J, Miller DJ, Rock CO J Biol Chem. 2020 Apr 21. pii: RA120.013336. doi: 10.1074/jbc.RA120.013336. PMID:32317282 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also Enoyl-Acyl-Carrier Protein Reductase 3D structures

Proteopedia Page Contributors and Editors (what is this?)

OCA